Cargando…

Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Despite being the fourth-leading cause of cancer-related deaths worldwide, pancreatic ductal adenocarcinoma (PDAC) lacks early diagnostic methods. We performed mRNA sequencing on peripheral blood mononuclear cells isolated from PDAC patients and identified IL-7R as a potential early...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Sung-Ill, Cho, Jae-Hee, Kim, So-Young, Hong, In-Young, Park, Joon-Seong, Lee, Hye-Sun, Park, Goeun, Kim, Jong-Kyoung, Lee, Hyung-Keun, Lee, Dong-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834093/ https://www.ncbi.nlm.nih.gov/pubmed/35159120 http://dx.doi.org/10.3390/cancers14030853

Ejemplares similares

Characterization of Circulating IL-7R Positive Cell Populations for Early Detection of Pancreatic Ductal Adenocarcinoma
por: Heo, Sun-Hee, et al.
Publicado: (2021)

Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
por: Jang, Sung Ill, et al.
Publicado: (2023)

Prognostic Value of VEGF in Human Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004)

An Immunological Glance on Pancreatic Ductal Adenocarcinoma
por: Melzer, Michael Karl, et al.
Publicado: (2020)

Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma
por: Koh, Youngil, et al.
Publicado: (2023)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Pancreaticoduodenectomy of Pancreatic Ductal Adenocarcinoma in the Elderly
por: Kang, Chang Moo, et al.
Publicado: (2007)

Laparoscopic pancreaticoduodenectomy in pancreatic ductal adenocarcinoma
por: Choi, Munseok, et al.
Publicado: (2021)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Prognostic Significance of Maspin in Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004)

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
por: Park, Hyung Soon, et al.
Publicado: (2016)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
por: Kim, Hye Jin, et al.
Publicado: (2019)

Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma
por: Rho, Seoung Yoon, et al.
Publicado: (2019)

Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma
por: Kim, Im-kyung, et al.
Publicado: (2019)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
por: Song, Byeong Geun, et al.
Publicado: (2021)

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
por: Kim, Hyemin, et al.
Publicado: (2021)

Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma
por: Park, Jae Keun, et al.
Publicado: (2020)

Comparison of Minimally Invasive versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis
por: Kwon, Jaewoo, et al.
Publicado: (2020)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Validation of the eighth edition of the American Joint Committee on Cancer staging system and proposal of an improved staging system for pancreatic ductal adenocarcinoma
por: Park, Min Young, et al.
Publicado: (2019)

Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review
por: Elbanna, Khaled Y., et al.
Publicado: (2020)

Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma
por: Ryu, Kum Hei, et al.
Publicado: (2023)

Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma
por: Hong, Sarang, et al.
Publicado: (2021)

Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma
por: Igata, Yu, et al.
Publicado: (2023)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
por: Sung, Min Kyu, et al.
Publicado: (2021)

GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2021)

Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
por: Park, Yejong, et al.
Publicado: (2021)

Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients
por: Kim, Mi-Ju, et al.
Publicado: (2017)

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021)

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
por: Cho, In Kuk, et al.
Publicado: (2020)

Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients
por: Kwon, Jaewoo, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Sclerosing encapsulating peritonitis in a dog with pancreatic ductal adenocarcinoma
por: Tsukada, Yusuke, et al.
Publicado: (2022)

Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining
por: Jang, Sung Ill, et al.
Publicado: (2023)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma
por: Shin, Dong Woo, et al.
Publicado: (2022)

ATP Production Relies on Fatty Acid Oxidation Rather than Glycolysis in Pancreatic Ductal Adenocarcinoma
por: Lee, Jae-Seon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j67c49fve4r7nkkq85at8mfde1